Inclusion Criteria:  Criteria related to the population:  Male or Female aged between 18 and 35 years included Subject with phototype I to IV included Subject having signed his/her written informed consent for his/her participation in the study Subject who is currently not participating in another clinical study Subject affiliated to a social security system or health insurance, or is a beneficiary For woman of childbearing potential: use of an effective method of contraception and using it during the whole duration of the study  Criteria related to diseases and general health:  Subject with oily, blemished skin and dilated pores on the face including open and closed comedones of the retention type (on the forehead, temporal areas and nose wings) and some inflammatory lesions:  Retention aspect: microcomedones and open comedones count on the forehead (> 10) Inflammatory aspect: lesions ≤ 10 count on the whole face  Exclusion Criteria:  Criteria related to the population:  For woman of childbearing potential: subject pregnant or breastfeeding or planning to be pregnant during the study Subject having already known allergy to latex Subject having already known allergy to the test product or associated product components Subject having scar(s) or other skin characteristic on the study areas (forehead, temporal areas and nose wings) and which, size is not compatible with the study realization Subject who, has planned to apply exfoliating, keratolytic and/or self-tanning products on the face within 2 weeks prior to inclusion. Subject who, has planned to be exposed to the natural or artificial UV during the study Subject who is not likely to be compliant with study-related requirements Subject deprived of freedom by administrative or legal decision or under guardianship  Criteria related to diseases and general health:  - Inflammatory or immunological dermatosis (atopic dermatitis, psoriasis, severe inflammatory acne, cutaneous seborrhoeic dermatitis, vitiligo of the face..) of the face, or other dermatological face illness in progress at the time of inclusion on the sample areas (pigmentation of the sample areas by melasma, solar erythema or artificial post UV...)  Criteria related to treatments  Facial treatments :  Any topical anti-acne antibiotics (topical Erythromycin or topical Dalacin) applied during more than 5 consecutive days within 4 weeks before the inclusion Any topical treatment (dermo corticoids, retinoids, antibiotics, antifungals…) ongoing or applied within 4 weeks before the inclusion Oral intake of antibiotic, zinc gluconate or hormonal anti-acne treatments, ongoing or taken during more than 5 consecutive days within the month before the inclusion Oral intake of isotretinoin within 6 months before the inclusion Anti-inflammatory treatments (steroids or no steroids) according to the investigator's assessment Hormonal contraception established or modified within 3 months before the inclusion Application of skin care product containing exfoliating, keratolytic or self-tanning ingredients applied on the face within 15 days before the inclusion Oral treatment (cardiovascular, endocrinal, rheumatological, urogenital, neuropsychiatric, immunosuppressant) established within 2 months before the inclusion not stabilized Hygiene, skin care or make-up habits modified within less than one month before the inclusion